8-K current report · filed Nov 5, 2026

ANI PHARMACEUTICALS INC (ANIP) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.1ANIP overview

Short answer

ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

ANI PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary contained in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation covers third-quarter 2026 results
  • Presentation addresses proposed Egetis Therapeutics acquisition
  • Analyst and investor conference call and webcast held November 5, 2026
  • Exhibit 99.2 provides the presentation, with materials available through investor relations:VEVENT

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $290.8M, up 27.6%, with adjusted EBITDA $83.3M, up 39.8%, signaling strong operating momentum
  • Cortrophin Gel revenue $138.7M, up 36.1%, but specialty-pharmacy capacity constrained conversion from demand into treated patients
  • 2026 guidance narrowed to $1,085M-$1,125M revenue and $290M-$300M adjusted EBITDA
  • Cortrophin guidance reduced to $480M-$500M, while adjusted EPS guidance increased to $9.37-$9.71
  • Proposed Egetis acquisition valued at approximately $560M, or $434M net of expected PRV proceeds, expanding rare-disease exposure
  • Acquisition requires 90% acceptance and regulatory approvals, with financing from cash on hand and new debt

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 revenue $290.8M, up 28% YoY, with adjusted non-GAAP EBITDA $83.3M, up 40%
  • Rare Disease revenue $138.7M, up 36% YoY, driven by Cortrophin Gel momentum and gout expansion
  • Egetis offer values equity at SEK 5.6B, approximately $560M, with net enterprise value approximately $434M
  • Financing includes existing cash and up to $300M debt, with expected post-close net leverage of approximately 2.7x
  • EMCITATE offers over $300M peak-sales potential, but acquisition expected to dilute adjusted non-GAAP EPS in Year 1

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANI PHARMACEUTICALS INC 8-K filings

Get the next ANIP 8-K as it lands

Follow ANIP for push alerts, or ask the research agent what this filing means.